A new minimally invasive method for the treatment of diseases of the thoracic aortic arch

Thousands of patients have new hope for treating thoracic aortic arch disease with a new minimally invasive treatment being tested at UC Davis Health. UC Davis Medical Center is one of 30 centers in the United States authorized to examine the NEXUS Aortic Arch Stent Graft System.

The non-randomized clinical trial is known as TRIOMPHE. He will evaluate the safety and effectiveness of the NEXUS system in treating diseases of the thoracic aorta that affect the aortic arch, the upper part of the main artery that drains blood away from the heart. Bob Kiayi, Chief of Cardiothoracic Surgery, and Stephen Maximus, Associate Professor, Department of Vascular Surgery, are principal investigators.

“Treatment of patients with thoracic aortic arch disease presents many challenges due to size, shape and location,” Maximus explained. “The current treatment for these pathologies is only open surgical correction. Sternotomy is currently required [opening of the chest] and hypothermic circulatory arrest (suspension of blood flow at very low body temperatures). Despite significant advances, open surgical repair of the thoracic aortic arch has a relatively high mortality and morbidity rate, and for these reasons, many patients are not suitable.”

We are pleased to offer patients a minimally invasive option to treat a condition that could previously only be treated with major open surgery. With this system, we have the potential to create a better experience for patients and improve outcomes.”—Stephen Maximus

The NEXUS system was designed to address the anatomy of the aortic arch. The surgeon inserts it by traveling through the patient’s vascular system under fluoroscopic guidance (X-rays), starting with a small incision or needle prick near the groin. This approach is called endovascular.

NEXUS is designed to make minimally invasive recovery possible for more patients and possibly reduce surgical risks. This can lead to shorter procedure times and hospital stays, as well as potentially better outcomes.

“We are excited to offer patients a minimally invasive option to treat a condition that could previously only be treated with major open surgery,” Maximus said. “With this system, we have the potential to create a better experience for patients and improve outcomes.”

For more information about TRIOMPHE clinical trials and the NEXUS device, visit the company’s website.